Aplastic Anemia (Hematology) - Drugs in Development, 2021

September 2021 | 138 pages | ID: A8044489FC45EN
Global Markets Direct

Abstracts

Aplastic Anemia (Hematology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Aplastic Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Aplastic Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Aplastic Anemia (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Aplastic Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Aplastic Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Aplastic Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Aplastic Anemia (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Aplastic Anemia (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Aplastic Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Aplastic Anemia - Overview
Aplastic Anemia - Therapeutics Development
Aplastic Anemia - Therapeutics Assessment
Aplastic Anemia - Companies Involved in Therapeutics Development
Aplastic Anemia - Drug Profiles
Aplastic Anemia - Dormant Projects
Aplastic Anemia - Discontinued Products
Aplastic Anemia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Aplastic Anemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Aplastic Anemia - Pipeline by Acceleron Pharma Inc, 2021
Aplastic Anemia - Pipeline by Amgen Inc, 2021
Aplastic Anemia - Pipeline by ASC Therapeutics Inc, 2021
Aplastic Anemia - Pipeline by Bellicum Pharmaceuticals Inc, 2021
Aplastic Anemia - Pipeline by BioLineRx Ltd, 2021
Aplastic Anemia - Pipeline by Cell Source Inc, 2021
Aplastic Anemia - Pipeline by Cellenkos Inc, 2021
Aplastic Anemia - Pipeline by Elixirgen Therapeutics Inc, 2021
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Aplastic Anemia - Pipeline by Gamida Cell Ltd, 2021
Aplastic Anemia - Pipeline by Hangzhou Zede Pharmaceutical Technology Co Ltd, 2021
Aplastic Anemia - Pipeline by HemoGenyx Pharmaceuticals Plc, 2021
Aplastic Anemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Aplastic Anemia - Pipeline by Novartis AG, 2021
Aplastic Anemia - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Aplastic Anemia - Pipeline by Pfizer Inc, 2021
Aplastic Anemia - Pipeline by Regen BioPharma Inc, 2021
Aplastic Anemia - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Aplastic Anemia - Dormant Projects, 2021
Aplastic Anemia - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Aplastic Anemia, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021